Medicare Organization Report Enhancing (MORE) Summaries Act

S. 3799 (117th); Implementation of "PREVENT Pandemics" Act; Issues related to pandemic prevention; testing; surveillance. H.R. 9029; Draft Senate Bill; Labor, HHS Appropriations Bill 2025; Issues related to HHS; pandemic preparedness, vaccines; gene synthesis screening; CDC. Draft Bills; Pandemic All Hazardous Prevent Act (PAHPA); Issues related to MCM PRV; Gene Synthesis Screening. Draft Bills; Securing Gene Synthesis Act; Issues related to gene synthesis products and screening S. 3558; H.R. 7085; A bill to prohibit contracting with certain biotechnology providers, and for other purposes.; All titles and sections. Issues related to COVID-19 testing and vaccine studies; Vaccine durability and efficacy; genomic sequencing; medical countermeasures; autoinjectors; pandemic preparedness and response. Issues related to CDC authorization and appropriations;Consensus Based Entity. Issues related to military health and rehabilitation (neurotechnology).

Client expense: $260,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 8070; S. 4638; National Defense Authorization Act for Fiscal Year 2025; Issues and provisions related to Title II - O&M; Title III - Procurement; Title IV - RDT&E, Title VI - Defense Health, the Military and National Intelligence programs and environmental restoration and PFAS destruction Technology. Issues related to Senate provision on Price Anderson Act H.R. 8512; S. 4443; Intelligence Authorization Act for FY25; Intelligence Activities including cyber, microelectronics, biotechnology, biopreparedness, biosecurity and intelligence matters relating to China Draft Bills; Defense Appropriations Bill, 2025; Issues and provisions related to Title II - O&M; Title III - Procurement; Title IV - RDT&E, Title VI - Defense Health, and the Military and National Intelligence programs. S. 3799; PREVENT Pandemics Act; Biosecurity; Biopreparedness; Biotechnology; Congressionally Directed Medical Research Program; Spinal Cord Injury Research Program; Neurotechnology S. 3558; H.R. 7085; A bill to prohibit contracting with certain biotechnology providers, and for other purposes.; All titles and sections. Issues related to NNSA weapons and nonproliferation programs. Issues related to Semiconductor / Microelectronics Manufacturing and Research; implementation of CHIPS and Science Act. Issues related to military health and rehabilitation; veteran rehabilitation; neurotechnology. Issues related to Biosecurity.

Client expense: $260,000 · Firm income: Not reported

Draft Bills; National Defense Authorization Act for Fiscal Year 2025; Issues and provisions related to Title II - O&M; Title III - Procurement; Title IV - RDT&E, Title VI - Defense Health, the Military and National Intelligence programs and environmental restoration and PFAS destruction Technology. Issues related to Senate provision on Price Anderson Act Draft Bills;Intelligence Authorization Act for FY25; Intelligence Activities including cyber, microelectronics, biotechnology, biopreparedness, biosecurity and intelligence matters relating to China Draft Bills; Defense Appropriations Bill, 2025; Issues and provisions related to Title II - O&M; Title III - Procurement; Title IV - RDT&E, Title VI - Defense Health, and the Military and National Intelligence programs. S. 3799; PREVENT Pandemics Act; Biosecurity; Biopreparedness; Biotechnology; Congressionally Directed Medical Research Program; Spinal Cord Injury Research Program; Neurotechnology S. 3558; A bill to prohibit contracting with certain biotechnology providers, and for other purposes.; All titles and sections. Issues related to NNSA weapons and nonproliferation programs. Issues related to Semiconductor / Microelectronics Manufacturing and Research; implementation of CHIPS and Science Act. Issues related to military health and rehabilitation; veteran rehabilitation; neurotechnology. Issues related to Biosecurity.

Client expense: $270,000 · Firm income: Not reported

S. 3799 (117th); Implementation of "PREVENT Pandemics" Act; Issues related to pandemic prevention; testing; surveillance. Draft Bills; Labor, HHS Appopriations Bill 2025; Issues related to HHS; pandemic preparedness, vaccines; gene synthesis screening; CDC. Draft Bills; Pandemic All Hazardous Prevent Act (PAHPA); Issues related to MCM PRV; Gene Synthesis Screening. Draft Bills; Securing Gene Synthesis Act; Issues related to gene synthesis products and screening S. 3558; A bill to prohibit contracting with certain biotechnology providers, and for other purposes.; All titles and sections. Issues related to COVID-19 testing and vaccine studies; Vaccine durability and efficacy; genomic sequencing; medical countermeasures; autoinjectors; pandemic preparedness and response. Issues related to CDC authorization and appropriations;Consensus Based Entity. Issues related to military health and rehabilitation (neurotechnology).

Client expense: $270,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 3799 (117th); Implementation of "PREVENT Pandemics" Act; Issues related to pandemic prevention; testing; surveillance. H.R. 4634; S. 2302; Labor, HHS Appopriations Bill 2024; Issues related to HHS; pandemic preparedness, vaccines; gene synthesis screening; CDC. Draft Bills; Pandemic All Hazardous Prevent Act (PAHPA); Issues related to MCM PRV; Gene Synthesis Screening. Draft Bills; Securing Gene Synthesis Act; Issues related to gene synthesis products and screening Issues related to COVID-19 testing and vaccine studies; Vaccine durability and efficacy; genomic sequencing; medical countermeasures; autoinjectors; pandemic preparedness and response. Issues related to military health and rehabilitation (neurotechnology).

Client expense: $220,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2760; S. 2226; National Defense Authorization Act for Fiscal Year 2024; Issues and provisions related to Title II - O&M; Title III - Procurement; Title IV - RDT&E, Title VI - Defense Health, the Military and National Intelligence programs and environmental restoration and PFAS destruction Technology. Issues related to Senate provision on Price Anderson Act. Draft Bill; Intelligence Authorization Act for FY24; Intelligence Activities including cyber, microelectronics, biotechnology, biopreparedness, biosecurity and intelligence matters relating to China H.R. 4365; S. 2587; Defense Appropriations Bill, FY24; Issues and provisions related to Title II - O&M; Title III - Procurement; Title IV - RDT&E, Title VI - Defense Health, and the Military and National Intelligence programs. S. 3799; PREVENT Pandemics Act;Biosecurity; Biopreparedness; Biotechnology; Congressionally Directed Medical Research Program; Spinal Cord Injury Research Program; Neurotechnology Issues related to NNSA weapons and nonproliferation programs. Issues related to Semiconductor / Microelectronics Manufacturing and Research; implementation of CHIPS and Science Act. Issues related to military health and rehabilitation; veteran rehabilitation; neurotechnology. Issues related to Biosecurity.

Client expense: $220,000 · Firm income: Not reported

H.R. 2760; S. 2226; National Defense Authorization Act for Fiscal Year 2024; Issues and provisions related to Title II - O&M; Title III - Procurement; Title IV - RDT&E, Title VI - Defense Health, the Military and National Intelligence programs and environmental restoration and PFAS destruction Technology. Issues related to Senate provision on Price Anderson Act. Draft Bill; Intelligence Authorization Act for FY24; Intelligence Activities including cyber, microelectronics, biotechnology, biopreparedness, biosecurity and intelligence matters relating to China H.R. 4365; S. 2587; Defense Appropriations Bill, FY24; Issues and provisions related to Title II - O&M; Title III - Procurement; Title IV - RDT&E, Title VI - Defense Health, and the Military and National Intelligence programs. S. 3799; PREVENT Pandemics Act;Biosecurity; Biopreparedness; Biotechnology; Congressionally Directed Medical Research Program; Spinal Cord Injury Research Program; Neurotechnology Issues related to NNSA weapons and nonproliferation programs. Issues related to Semiconductor / Microelectronics Manufacturing and Research; implementation of CHIPS and Science Act. Issues related to military health and rehabilitation; veteran rehabilitation; neurotechnology.

Client expense: $250,000 · Firm income: Not reported

S. 3799 (117th); Implementation of "PREVENT Pandemics" Act; Issues related to pandemic prevention; testing; surveillance. H.R. 4634; S. 2302; Labor, HHS Appopriations Bill 2024; Issues related to HHS; pandemic preparedness, vaccines; gene synthesis screening; CDC. Draft Bills; Pandemic All Hazardous Prevent Act (PAHPA); Issues related to MCM PRV; Gene Synthesis Screening. Draft Bills; Securing Gene Synthesis Act; Issues related to gene synthesis products and screening Issues related to COVID-19 testing and vaccine studies; Vaccine durability and efficacy; genomic sequencing; medical countermeasures; autoinjectors; pandemic preparedness and response. Issues related to military health and rehabilitation (neurotechnology).

Client expense: $250,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 3799 (117th); Implementation of "PREVENT Pandemics" Act; Issues related to pandemic prevention; testing; surveillance. H.R. 4634; S. 2302; Labor, HHS Appopriations Bill 2024; Issues related to HHS; pandemic preparedness, vaccines; CDC. Draft Bills; Pandemic All Hazardous Prevent Act (PAHPA); Issues related to MCM PRV; Gene Synthesis Screening. Issues related to COVID-19 testing and vaccine studies; Vaccine durability and efficacy; genomic sequencing; pandemic preparedness and response. Issues related to military health and rehabilitation (neurotechnology).

Client expense: $240,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2760; S. 2226; National Defense Authorization Act for Fiscal Year 2024; Issues and provisions related to Title II - O&M; Title III - Procurement; Title IV - RDT&E, Title VI - Defense Health, the Military and National Intelligence programs and environmental restoration and PFAS destruction Technology. Draft Bill; Intelligence Authorization Act for FY24; Intelligence Activities including cyber, microelectronics, biotechnology, biopreparedness and intelligence matters relating to China H.R. 4365; Draft Bill; Defense Appropriations Bill, FY24; Issues and provisions related to Title II - O&M; Title III - Procurement; Title IV - RDT&E, Title VI - Defense Health, and the Military and National Intelligence programs. S. 3799; PREVENT Pandemics Act;Biosecurity; Biopreparedness; Biotechnology; Congressionally Directed Medical Research Program; Spinal Cord Injury Research Program; Neurotechnology Issues related to NNSA weapons and nonproliferation programs. Issues related to Semiconductor / Microelectronics Manufacturing and Research; implementation of CHIPS and Science Act. Issues related to military health and rehabilitation; veteran rehabilitation; neurotechnology.

Client expense: $240,000 · Firm income: Not reported

S. 3799 (117th); Implementation of "PREVENT Pandemics" Act; Issues related to pandemic prevention; testing; surveillance. Draft Bills; Labor, HHS Appopriations Bill 2024; Issues related to HHS; pandemic preparedness, vaccines; CDC. Draft Bills; Pandemic All Hazardous Prevent Act (PAHPA); Issues related to MCM PRV. Issues related to COVID-19 testing and vaccine studies; Vaccine durability and efficacy; genomic sequencing; pandemic preparedness and response. Issues related to military health and rehabilitation (neurotechnology).

Client expense: $320,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

340B Drug Discount Program ---340B Accountability Act ---Executive Order on Access to Affordable Life-Saving Medications ---Program Implementation & Oversight ---PROTECT 340B Act Accelerated Approval Alternative Funding Programs Biodefense Research, Development and Procurement Issues (Non-Funding) ---American Pandemic Preparedness Plan (AP3) ---Disease X ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 ---MCM PRV Program ---Reauthorization of PAHPA ---Tropical Disease Priority Review Voucher (PRV) Program ---White House National Biodefense Strategy Biosimilars ---BIOSIM Act ---BSUFA Negotiations ---Coding ---Implementation and Reauthorization of the Biosimilar User Fee Act of 2022 ---Interchangeability and Pharmacy Substitution ---Protecting Consumer Access to Generic Drugs Act ---Reimbursement Coronavirus (COVID-19) Pandemic ---H.R.834: Pandemics Require Evaluating, Planning, And Responding Effectively (PREPARE) Act ---H.R.2617: Consolidated Appropriations Act of 2023 ---S.2327: Seniors Prescription Drug Relief Act ---S.3799: Prepare for and Respond to Existing Viruses, Emerging New Threats and (PREVENT) Pandemics Act ---S.4317: SAFE TO WORK Act ---S.4509: Vaccine And Coverage Certainty (VACC) Act ---Access to Generic Drugs Act of 2021 ---COVID-19 Lessons Learned ---COVID-19 Pricing-Related Provisions ---COVID-19 Vaccine Distribution ---Defense Production Act (DPA) ---Drug Supply Chain Management ---Healthcare Disparities ---Medicare Reimbursement Policies ---Monoclonal Antibody Coverage and Utilization ---Patient Cost-Sharing and Smoothing ---R&D Funding for Medical Countermeasures ---Restrictions on Intellectual Property Rights ---Senate HELP Pandemic Preparedness White Paper ---Supply Chain Issues ---Temporarily Refundable R&D Credit ---TRIPS Waiver ---WHO Pandemic Preparedness Accord Climate Change ---H.R.2617: Consolidated Appropriations Act of 2023 ---Implementation of the Inflation Reduction Act (IRA) of 2022 Data Privacy ---H.R.8152: American Data Privacy and Protection Act Diagnostics and Personalized Medicine Regulation and Oversight Diversity & Inclusion ---S.3799: Prepare for and Respond to Existing Viruses, Emerging New Threats and (PREVENT) Pandemics Act ---Decentralized Clinical Trials Drug Evaluation and Review ---COVID-19 Lessons Learned ---FDA Management and Financial Accountability Drug Importation Drug Manufacturing, Quality & Distribution ---Advanced Manufacturing ---Counterfeiting ---Drug Shortages ---Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy ---Supply Chain Integrity and Traceability Drug Patenting ---H.R.2883/S.1485: Stop Stalling Access to Affordable Medications ---H.R.2891/S.1428: Preserve Access to Affordable Generics and Biosimilars Act ---S.79/H.R.1717: Interagency Patent Coordination and Improvement Act of 2023 ---S.113: Prescription Pricing for the People Act of 2023 ---S.142: Preserve Access to Affordable Generics and Biosimilars Act ---S.148: Stop STALLING Act ---S.150: Affordable Prescriptions for Patients Act of 2023 ---S.1128 118th Congress (2023-2024): A bill to establish special rules relating to information provided with respect to drug applications concerning method of use patents ---Affordable Prescriptions for Patients Act ---Interagency Patent Coordination and Improvement Act ---Restrictions on Intellectual Property Rights Drug Pricing ---H.R.1790: Biologics Competition Act of 2023 ---H.R.2139/S.908: Medicare Drug Price Negotiation Act ---H.R.2148/S.909: Prescription Drug Price Relief Act ---H.R.2617: Consolidated Appropriations Act of 2023 ---S.79/H.R.1717: Interagency Patent Coordination and Improvement Act of 2023 ---S.113: Prescription Pricing for the People Act of 2023 ---S.142: Preserve Access to Affordable Generics and Biosimilars Act ---S.148: Stop STALLING Act ---S.150: Affordable Prescriptions for Patients Act of 2023 ---S.775: Increasing Transparency in Generic Drug Application ---S.1067: Ensuring Timely Access to Generics ---S.1128 118th Congress (2023-2024): A bill to establish special rules relating to information provided with respect to drug applications concerning method of use patents ---Access to Innovative Treatments Act ---Affordable Prescriptions for Patients Act ---COVID-19 Pricing-Related Provisions ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Lower Costs, More Cures Act ---National Coverage Determination ---Pharmacy Benefit Manager Transparency Act ---Prescription Pricing for the People Act Foreign Drug Data Protection Laws Funding for Antimicrobial Resistance (AMR) Programs ---FY 2024 Appropriations ---H.R.2617: Consolidated Appropriations Act of 2023 ---National Defense Authorization Act for FY 2023 ---DISARM Act ---Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---FY 2024 Appropriations ---H.R.2617: Consolidated Appropriations Act of 2023 ---Funding for Strategic National Stockpile ---Health Defense Operations Funding Designation ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Reauthorization of PAHPA Funding for FDA ---FY 2024 Appropriations ---H.R.2617: Consolidated Appropriations Act of 2023 ---H.R.7667: The Food and Drug Amendments of 2022 ---H.R.8239: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act ---S.4348: Food and Drug Administration Safety and Landmark Advancements Act of 2022 ---Prescription Drug User Fee Act (PDUFA) VII Priorities Funding for Health Resources and Services Administration (HRSA) ---H.R.2617: Consolidated Appropriations Act of 2023 Funding for National Institutes of Health ---FY 2024 Appropriations ---H.R.2617: Consolidated Appropriations Act of 2023 ---Advanced Research Projects Agency for Health (ARPA-H) Act Funding for the Centers for Disease Control and Prevention Vaccine Programs ---FY 2024 Appropriations ---H.R.2617: Consolidated Appropriations Act of 2023 ---Funding for 2022-2023 Influenza Season Preparedness and Response ---Funding for Routine Immunization Infrastructure during Pandemic ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Funding for the HHS Office of Infectious Disease and HIV/AIDS Policy ---FY 2024 Appropriations ---H.R.2617: Consolidated Appropriations Act of 2023 Generic Drug Entry ---S.148: Stop STALLING Act ---Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act ---Enhanced Access to Affordable Medicines Act ---Generic Drug Application Review Reforms ---Increasing Transparency in Generic Drug Applications Act ---Incentives for Generic Entry Medicaid ---Alternative Payment Arrangements for Gene Therapies ---Average Manufacturer Price Calculations ---Coverage of Accelerated Approval Products ---Drug Benefit Design ---Medicaid VBPs for Patients (MVP) Act ---Pharmacy Benefit Manager Transparency Act ---Pricing and Rebates ---Value-Based Purchasing (VBP) Rule Opioid Crisis ---Coverage and Reimbursement ---Non-Opioid Analgesics Orphan Drug Issues ---H.R.5566: Finding Orphan-Disease Remedies with Antifungal Research and Development (FORWARD) Act ---S.4185: Retaining Access and Restoring Exclusivity (RARE) Act ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Orphan Drug Tax Credit Rare Pediatric Disease Priority Review ---H.R.6888/S.4071: Helping Experts Accelerate Rare Treatments (HEART) Act ---H.R.1730: Speeding Therapy Access Today (STAT) Act Reimbursement and Coverage of Innovative Products ---H.R.2139/S.908: Medicare Drug Price Negotiation Act ---H.R.2148/S.909: Prescription Drug Price Relief Act ---H.R.9127: Mandating Exclusive Review of Individual Treatments (MERIT) Act ---S.2327: Seniors Prescription Drug Relief Act ---Access to Innovative Treatments Act ---Administration Rebate Rule ---CMMI Authority ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---In-Home Administration of Part B Drugs ---Lower Costs, More Cures Act ---National Coverage Determination ---Patient Cost-Sharing and Smoothing Vaccines and Infectious Diseases ---FY 2024 Appropriations ---H.R.2617: Consolidated Appropriations Act of 2023 ---H.R.9127: Mandating Exclusive Review of Individual Treatments (MERIT) Act ---S.4509: Vaccine and Coverage Certainty (VACC) Act ---Access to Innovative Treatments Act ---Adult Immunization ---DISARM Act ---Maternal Immunization ---MCM Manufacturing & Capacity ---MCM R&D Incentives ---Monoclonal Antibody Coverage and Utilization ---National Coverage Determination ---Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) ---Vaccine and Antimicrobial Resistance Product Development and Incentives ---Vaccine Injury Compensation Modernization Act ---Vaccine Injury Compensation Program ---Vaccine Quality Measure ---Vaccine Safety Vaccine Injury Compensation Program ---FY 2024 Appropriations ---H.R.2617: Consolidated Appropriations Act of 2023 ---S.3810: Countermeasure Injury Compensation Fund Amendment Act ---Vaccine Access Improvement Act ---Vaccine Injury Compensation Modernization Act ---VICP CICP (Discussion Draft)